BTIG Research Cuts GeneDx (NASDAQ:WGS) Price Target to $90.00

GeneDx (NASDAQ:WGS) had its price target dropped by research analysts at BTIG Research from $170.00 to $90.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s price target would indicate a potential upside of 32.49% from the company’s current price.

A number of other brokerages have also weighed in on WGS. Wall Street Zen lowered GeneDx from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. Jefferies Financial Group set a $150.00 target price on GeneDx in a research report on Monday, February 23rd. Canaccord Genuity Group set a $100.00 target price on GeneDx and gave the stock a “buy” rating in a research report on Monday, April 20th. Zacks Research lowered GeneDx from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 24th. Finally, Wells Fargo & Company reaffirmed an “overweight” rating on shares of GeneDx in a research report on Tuesday. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, GeneDx has a consensus rating of “Moderate Buy” and a consensus price target of $120.83.

GeneDx Price Performance

Shares of NASDAQ:WGS opened at $67.93 on Tuesday. The company has a quick ratio of 2.34, a current ratio of 2.46 and a debt-to-equity ratio of 0.16. GeneDx has a twelve month low of $55.17 and a twelve month high of $170.87. The stock’s 50 day moving average is $71.45 and its 200-day moving average is $107.17. The firm has a market capitalization of $1.99 billion, a price-to-earnings ratio of -90.57 and a beta of 2.06.

GeneDx (NASDAQ:WGS) last issued its earnings results on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). GeneDx had a positive return on equity of 14.73% and a negative net margin of 4.92%.The firm had revenue of $102.25 million for the quarter, compared to analyst estimates of $112.46 million. During the same period in the previous year, the company earned ($0.23) earnings per share. Sell-side analysts forecast that GeneDx will post 0.75 EPS for the current fiscal year.

Insider Activity

In related news, CEO Katherine Stueland sold 46,933 shares of the firm’s stock in a transaction dated Thursday, March 26th. The shares were sold at an average price of $63.17, for a total transaction of $2,964,757.61. Following the transaction, the chief executive officer directly owned 91,514 shares of the company’s stock, valued at $5,780,939.38. This trade represents a 33.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Bryan Dechairo sold 5,961 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $85.70, for a total transaction of $510,857.70. The SEC filing for this sale provides additional information. Insiders sold 109,989 shares of company stock valued at $7,888,023 over the last ninety days. Company insiders own 29.60% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in WGS. Royal Bank of Canada lifted its position in shares of GeneDx by 30.2% during the first quarter. Royal Bank of Canada now owns 29,479 shares of the company’s stock valued at $2,611,000 after purchasing an additional 6,840 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of GeneDx by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company’s stock valued at $677,000 after purchasing an additional 453 shares during the last quarter. NewEdge Advisors LLC increased its position in shares of GeneDx by 270,700.0% during the 1st quarter. NewEdge Advisors LLC now owns 2,708 shares of the company’s stock valued at $240,000 after purchasing an additional 2,707 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of GeneDx by 67.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 28,224 shares of the company’s stock valued at $2,500,000 after purchasing an additional 11,375 shares during the last quarter. Finally, Cetera Investment Advisers purchased a new stake in shares of GeneDx during the 2nd quarter valued at $249,000. 61.72% of the stock is owned by institutional investors.

Key Headlines Impacting GeneDx

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Strong underlying volume growth: management reported 34% year?over?year volume growth in exome and genome testing, supporting longer?term demand for the core business. GeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year Outlook
• Neutral Sentiment: Revenue and gross profit were higher year?over?year ($102.3M revenue; gross profit up ?17%), indicating growth despite near?term margin pressure. GeneDx Holdings Corp. (WGS) Stock Falls on Q1 2026 Earnings
• Neutral Sentiment: Conference call materials and transcript are available for more detail on drivers and cadence of margin recovery; listeners can assess management commentary for guidance color. GeneDx Holdings Corp. (WGS) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Q1 EPS missed materially: GAAP loss per share of ($0.28) vs. consensus loss of ($0.06), with revenue below estimates (~$102.25M vs. ~$112–114M est.), a primary catalyst for downward pressure. GeneDx Holdings Corp. (WGS) Reports Q1 Loss, Lags Revenue Estimates
• Negative Sentiment: Full?year revenue guidance markedly below consensus: management set FY revenue of roughly $475–$490M vs. street ~$549M, increasing downside risk to near?term estimates and valuation. GeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year Outlook
• Negative Sentiment: Profitability and cash flow stress: the quarter showed a large operating and net loss and meaningful operating cash outflow, which raises execution and financing concerns until margins and cash generation improve. GeneDx Holdings Corp. (WGS) Stock Falls on Q1 2026 Earnings
• Negative Sentiment: Insider selling: recent disclosure shows the CFO sold shares (~$25.6k reported) and several insiders have sold shares in recent months, which markets often view as a negative signal. Insider Selling: GeneDx (NASDAQ:WGS) CFO Sells $25,554.48 in Stock

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.